171 related articles for article (PubMed ID: 33801338)
1. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
[TBL] [Abstract][Full Text] [Related]
2. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
3. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
[TBL] [Abstract][Full Text] [Related]
4. Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra-large virtual screening.
Radaeva M; Morin H; Pandey M; Ban F; Guo M; LeBlanc E; Lallous N; Cherkasov A
Mol Inform; 2023 Aug; 42(8-9):e2300026. PubMed ID: 37193651
[TBL] [Abstract][Full Text] [Related]
5. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
Li H; Ban F; Dalal K; Leblanc E; Frewin K; Ma D; Adomat H; Rennie PS; Cherkasov A
J Med Chem; 2014 Aug; 57(15):6458-67. PubMed ID: 25062331
[TBL] [Abstract][Full Text] [Related]
6. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
7. Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.
Dalal K; Munuganti R; Morin H; Lallous N; Rennie PS; Cherkasov A
Methods Mol Biol; 2016; 1443():31-54. PubMed ID: 27246333
[TBL] [Abstract][Full Text] [Related]
8. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
[TBL] [Abstract][Full Text] [Related]
9. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
Gustafson JL; Neklesa TK; Cox CS; Roth AG; Buckley DL; Tae HS; Sundberg TB; Stagg DB; Hines J; McDonnell DP; Norris JD; Crews CM
Angew Chem Int Ed Engl; 2015 Aug; 54(33):9659-62. PubMed ID: 26083457
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
11. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
12. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
[TBL] [Abstract][Full Text] [Related]
14. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
Shen HC; Shanmugasundaram K; Simon NI; Cai C; Wang H; Chen S; Balk SP; Rigby AC
Mol Endocrinol; 2012 Nov; 26(11):1836-46. PubMed ID: 23023563
[TBL] [Abstract][Full Text] [Related]
15. Development of a High-Throughput Screening Assay for Small-Molecule Inhibitors of Androgen Receptor Splice Variants.
Monaghan AE; Porter A; Hunter I; Morrison A; McElroy SP; McEwan IJ
Assay Drug Dev Technol; 2022 Apr; 20(3):111-124. PubMed ID: 35333596
[TBL] [Abstract][Full Text] [Related]
16. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
17. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.
Lim M; Otto-Duessel M; He M; Su L; Nguyen D; Chin E; Alliston T; Jones JO
ACS Chem Biol; 2014 Mar; 9(3):692-702. PubMed ID: 24354286
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
19. The Small Molecule Antagonist KCI807 Disrupts Association of the Amino-Terminal Domain of the Androgen Receptor with ELK1 by Modulating the Adjacent DNA Binding Domain.
Soave C; Ducker C; Islam N; Kim S; Yurgelevic S; Nicely NI; Pardy L; Huang Y; Shaw PE; Auner G; Dickson A; Ratnam M
Mol Pharmacol; 2023 Apr; 103(4):211-220. PubMed ID: 36720643
[TBL] [Abstract][Full Text] [Related]
20. Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
Dalal K; Morin H; Ban F; Shepherd A; Fernandez M; Tam KJ; Li H; LeBlanc E; Lack N; Prinz H; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Sep; 157():1164-1173. PubMed ID: 30193215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]